Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVALUATE-HF: Sacubitril/Valsartan vs Enalapril on Aortic Stiffness in HFrEF
NCT02874794Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Aortic Characteristic Impedance (Zc) at 12 weeks. Started Aug 2016; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02874794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02874794.